Moderate TSH suppression may be better for patients with thyroid cancer
the ONA take:
According to a new study published online ahead of print in the journal Thyroid, researchers have found that moderate thyroid-stimulating hormone (TSH) suppression may be as beneficial as high suppression of the hormone responsible for driving thyroid cancer.
Higher TSH levels are associated with higher rates of thyroid cancer recurrence, but extreme suppression of TSH is linked with increased adverse events, such as arrhythmias and osteoporosis.
For the 30-year study, researchers analyzed data from 4,941 patients with thyroid cancer. Results showed that extreme TSH suppression offered no additional survival benefit compared with moderate TSH suppression in patients with high-risk disease. Moreover, researchers found that mild TSH suppression was beneficial for patients with low-risk thyroid cancer.
The findings suggest that further research is warranted to prospectively evaluate extreme TSH suppression versus moderate suppression in patients with high-risk thyroid cancer.
Moderate TSH suppression may be as beneficial as high suppression of the hormone responsible for driving the disease.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|